The U.S. Patent and Trademark Office issued a patent for Lineage Cell Therapeutics' stem cell-derived treatment for spinal cord injury.

Duchenne UK awarded researchers from Minneapolis-based University of Minnesota Medical School $945,000 to advance their work around a stem cell-based therapy to treat Duchenne muscular dystrophy.

A column by the right-leaning Independent Institute concerned the California Institute for Regenerative Medicine.

Here are five key developments in stem cell treatments for spine and orthopedics.

Fairlawn, Ohio-based Crystal Clinic Orthopaedic Center is using biologic therapies to treat anterior cruciate ligament and joint-related injuries.

Richard Kim, MD, is using stem cells to help relieve patient pain at his private practice in Saratoga Springs, N.Y.

Ortho Regenerative Technologies reported a successful pre-investigational drug meeting with the FDA in February and is now preparing for its rotator cuff phase I/II clinical trial.

In July, orthobiologics company Biogennix hit its best ever month for sales since its formation in 2009.

Biofirma, a subsidiary of IMAC Holdings, received "registered" status by the FDA.

A study published in Stem Cells Translational Medicine found that an injection of human amniotic fluid stem cells can be used to protect the spinal cord of a fetus from myelomeningocele.

John Tierney, DO, used Anika Therapeutics' injectable hyaluronic acid-based bone repair product in a patient.

Bioventus plans to expand Durolane, its hyaluronic acid joint-fluid osteoarthritis injection, into Australia and New Zealand.

Daniel Penello, MD, of Alexander Orthopaedic Associates in St. Petersburg, Fla., is a fellowship-trained orthopedic surgeon who specializes in hand and upper extremity surgery.

A group of orthobiologics experts established a Delphi panel process to set treatment standards for an outpatient stem cell procedure known as bone marrow concentrate.

PTC Therapeutics is leasing a 185,000-square-foot biologics-focused research space from Bristol-Myers Squibb, BioPharmaReport.com reports.

The California Institute for Regenerative Medicine has been instrumental in stem cell research since it was first established in 2004, but it faces closure in 2022 if a ballot initiative to get it more funding is unsuccessful. 

Discgenics treated the first patients in its clinical trial of intervertebral disc tissue for mild to moderate degenerative disc disease in Japan, reports Biospectrum Asia.

Andreas Gomoll, MD, implanted Cartiheal's Agili-C in two patients in an investigational device exemption study at Hospital for Special Surgery in New York City.

NanoFuse Biologics is launching its biologic in Panama City, Panama, through a partnership with medical distributor PTY Medical Group.

Camber Spine is widening its portfolio by tapping into the biologics market.